Table 1 Characteristics of 15 included studies
From: Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
First Author | Year | Sample Size | Interventions | Platinum-resistant | NOS score |
|---|---|---|---|---|---|
Hamanishi [9] | 2015 | 20 | Nivolumab | Yes | 8 |
Disis [10] | 2019 | 125 | Avelumab | NA | 8 |
Konstantinopoulos [11] | 2019 | 60 | Pembrolizumab + niraparib | Yes | 8 |
Liu [12] | 2019 | 9 | Atezolizumab | NA | 8 |
Liu [13] | 2019 | 38 | Nivolumab + bevacizumab | NA | 8 |
Matulonis [5] | 2019 | 376 | Pembrolizumab | NA | 8 |
Varga [14] | 2019 | 26 | Pembrolizumab | NA | 8 |
Walsh [6] | 2019 | 14 | Pembrolizumab + cisplatin + gemcitabine | Yes | 5 |
Lampert [15] | 2020 | 35 | Durvaluamb + olaparib | NA | 7 |
Lee [16] | 2020 | 23 | Pembrolizumab + pegylated liposomal doxorubicin | Yes | 7 |
Moroney [17] | 2020 | 12 | Atezolizumab + bevacizumab | Yes | 7 |
O'Cearbhaill [18] | 2020 | 40 | Durvalumab + pegylated liposomal doxorubicin | Yes | 5 |
Zamarin [19] | 2020 | 27 | Pembrolizumab + folate receptor alpha vaccine | Yes | 9 |
Zamarin [20] | 2020 | 100 | Nivolumab + ipilimumab vs nivolumab | NA | 7 |
Zsiros [7] | 2020 | 40 | Pembrolizumab + bevacizumab + cyclophosphamide | NA | 8 |